Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-03-22
2005-03-22
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S455000, C435S456000, C435S320100, C435S325000, C435S069100, C800S009000
Reexamination Certificate
active
06869935
ABSTRACT:
A method of treating ocular disorders (such as, for example, proliferative vitreoretinopathy or PVR) associated with replicating ocular cells by transfecting replicating ocular cells in vivo with a polynucleotide encoding an agent which is capable of providing for the inhibition, prevention, or destruction of the growth of the replicating ocular cells upon expression of the agent. The agent may be a viral thymidine kinase, and the polynucleotide encoding the agent may be contained in a retroviral vector. Once the replicating ocular cells are transduced with the retroviral vector, the patient is given a chemotherapeutic or interaction agent, such as ganciclovir, which kills the transfected replicating ocular cells.
REFERENCES:
patent: WO 9115580 (1991-10-01), None
Stedman's Medical Dictionary, 27thEdition (2002-2003), term: neovascularization.*
Chandler et al., Graife's Arch. Clin. Exp. Opthalmol., vol. 224, pp. 86-91, 1986.*
Mullen, C. A., Pharmac. Ther., vol. 63, pp. 199-207, 1994.*
Eck & Wilson, ‘Gene-Based Therapy’ in Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill: New York, Ninth Edition, pp. 77-101, 1996.*
Sakamoto et al., Opthalmology, vol. 102, pp. 1417-1424, 1995.*
Culver et al., “In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors,”Science, vol. 256, Jun. 12, 1992, pp. 1550-1552.
Freeman et al., “The Bystander Effect: Tumor Regression when a Fraction of the Tumor Mass is Genetically Modified”,Cancer Research, vol. 53, Nov. 1993, pp. 5274-5283.
Kimura H, Sakamoto T. Cardillo JA, Spee C, Hinton Dr., Gordon EM, Anderson WF, Ryan SJ. Retrovirus-mediated suicide gene transduction in the vitreous cavity of the eye: feasibility in prevention of proliferative vitreoretinopathy, Human Gene Therapy 7:799-808, 1.
Murata T, Hoffmann S, Ishibashi T, Spee C, Gordon EM, Anderson WF, Hinton Dr, Ryan SJ. Retrovirus-mediated gene transfer targeted to retinal photocoagulation sites. Diabetologia 41:500-506, 1998.
Behrens A, Gordon EM, Li L, Liu PX, Chen Z, Peng H, La Bree L, Anderson WF, Hall FL, McDonnell PJ. Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. Invest Ophthalmol Vis Sci 43:968-977, 2002.
Gordon EM, Chen ZH, Liu L, Whitely M, Liu L, Wei D, Groshen S, Hinton DR, Anderson WF, Beart RW, Hall FL. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Human Gene Therapy 12:193-204, 2001.
Lai C-M, Spilsbury K, Brankov M, Zaknich T, Rakoczy PE. Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. Exp Eye Res 75:625-634, 2002.
Lai CM, Shen WY, Constable IJ, Rakoczy PE. Preferential adenovirus-mediated transduction of cells at the sites of laser photcoagulation in the rat eye. Curr Eye Res 19:411-417, 1999.
Shichinohe T, Bochner BH Mizutani K, Nishida M, Hegerich-Gilliam S, Naldini L, Kasahara N. Cancer Gene Therapy 8:879-889, 2001.
Oshima Y, Sakamoto T, Hisatomis T, Tsutsumi C, Ueno H, Ishibashi T. Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy. Gene Therapy 9:1214-1220, 2002.
Mori K, Gehlbach P, Ando A, Wahlin K, Gunther V, McVery D, Wei L, Campochiaro PA. Intraocular adenoviral vector-mediated gene transfer on proliferative retinopathies. Invest Ophthalmol Vis Sci 43:1610-1615, 2002.
Lynch CM, Hara PS, Leonard JC, Williams JK, Dean RH, Geary RL. Adeno-associated virus vectors for vascular gene delivery. Circ Res 80:497-505, 1997.
Teramoto S, Ishii T, Matsuse T. Variables pertinent to the efficiency of adeno-associated virus (AAV) vectors mediated gene transfer to human vascular endothelial cells. Hypertesnion Res 24:437-443, 2001.
Auricchio A, Behling KC, Maguire AM, O'Conner EE, Bennett J, Wilson JM, Tolentino MJ. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Therapy 6:490-494, 2002.
Igarashi T, Miyake K, Kato K, Watanabe A, Ishizaki M, Ohara K, Shimada T. Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Therapy 10:219-226, 2003.
Murthy RC, McFarland TJ, Yoken J, Chen S, Barone C, Burke D, Zhang Y, Appukuttan B, Stout JT. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophthalmol Vis Sci 44:1837-1842, 2003.
Bennett J, Maguire AM. Gene Therapy for Ocular Disease. Molec Ther 1:501-504, 2002.
Murata T, Kimura H, Sakamoto T, Osusky R, Spee C. Stout TJ, Hinton DR, Ryan SJ. Ocular gene therapy: experimental studies and clinical possibilities. Ophthal Res 29:242-251, 1997.
Sakamoto, et al.,Investigative Opthomology and Visual Science, vol. 35, No. 4, Abstract 2391-74 (Mar. 15, 1994).
Sakamoto, et al., ARVO Abstract (Mar. 1995).
Kimura, et al., Gene Therapy Steamboat Abstract (1995).
Spec, et al, Gene Therapy Steamboat Abstract (1995).
Charteris,Br. J. Opthomol. vol. 79, pp. 953-960 (1995).
Sakamoto, et al.,Opthomology, vol. 102, No. 10, pp. 1417-1424 (Oct. 1995).
Stout,Opthomology, vol. 104, No. 10, pp. 1415-1416 (Oct. 1995).
Kimura, et al., ARVO Abstract (Mar. 1996).
Schubert, et al., ARVO Abstract (Mar. 1996).
Mullen,Pharmac. Ther. vol. 63, pp. 199-207 (1994).
Culver, et al., T.I.G., vol. 10, No. 5, pp. 174-178 (1994).
Marshall,Science, vol. 269, pp. 1050-1055 (1995).
Miller, et al.,FASEB, vol. 9, pp. 190-199 (1995).
Li, et al.,Investigative Opthomology&Visual Science, vol. 35, No. 5, pp. 2543-2549 (Apr. 1994).
Orkin, et al.,Report and Recommendations(Dec. 7, 1995).
Ledley,Haman Gene Therapy, vol. 2, pp. 77-83 (1991).
Anderson W. French
Hinton David
Ryan Stephen J
Crouch Deborah
Fish & Richardson P.C.
Ton Thai-an N.
University of Southern California
LandOfFree
Gene Therapy for proliferative vitreoretinopathy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene Therapy for proliferative vitreoretinopathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene Therapy for proliferative vitreoretinopathy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3375470